Deutsche Bank initiated coverage of DexCom with a Buy rating and $86 price target. The company "could be turning a corner" as its recent investor day eased concerns around the level and durability of its continuous glucose market's user and revenue growth outlook, the analyst tells investors in a research note. The firm believes many of DexCom's overhangs have or are starting to fade. The shares warrant a premium multiple, adds Deutsche Bank.
